Immunotherapy Advances

🛡️ This #PublishingIntegrityWeek, BSI journals are tackling papermills, promoting AI transparency, DEI & accessibility, and supporting ethical research in immunology.

Read more 👉 https://bit.ly/4odyvAZ

New review by Blee et al. “Turning the Tide: Harnessing Vaccines & Viruses to Fight Cancer” 🚀

How advanced preclinical models can boost cancer vaccines & oncolytic viruses 👉 https://bit.ly/4oLO7Nk

#CancerResearch #Immunotherapy

🧬 Therapeutic cancer vaccines are back in focus! Advances in neo-antigen T cells, dendritic cell biology, and mRNA tech are paving the way for next-gen immunotherapy.

Read the Open Access review: https://bit.ly/4cefxGm

#CancerVaccines #Immunotherapy #mRNA #Oncology

🦠 DC3s in solid tumours can prime T cells and influence outcomes—boosting survival in some cancers, but promoting immunosuppression in others.

👉 https://bit.ly/3T2blRg

#Immunotherapy #CancerImmunology

🔬 First head-to-head comparison of nuclear imaging for tumour CD8⁺ T cells shows [⁸⁹Zr]Zr-anti-CD8-IgG2a(silent) & [⁸⁹Zr]Zr-OT-I track T-cell infiltration & migration, aiding immunotherapy strategies.

👉 https://bit.ly/4ncWCzv

#Immunotherapy #CD8Tcells #CancerResearch

From CAR-NK cells to checkpoint inhibitors, Blunt & Khakoo review how boosting NK-cell function could transform cancer therapy.

🔓 Open access: https://bit.ly/4j8dKEW

#Immunotherapy #NKcells #CancerResearch

New study shows switching between Humira® and AVT02 in chronic plaque psoriasis does not alter cellular immunogenicity.

Novel EVCIA approach confirms comparable T cell responses, supporting interchangeability.

🔗 Open access: https://bit.ly/3J8pESs

#Immunology #Psoriasis

Tracking CD8+ T cells in tumours is key for immunotherapy research. Our new study compares nuclear imaging methods to see which best reflects T cell infiltration.

🔗 Open access: https://bit.ly/4ncWCzv

#Immunotherapy #CD8TCells #CancerResearch

🏆Following last week's exciting #NobelPrize announcement, the BSI journals have created a new virtual issue.

🔎Check it out for must-read articles on peripheral immune tolerance, including a paper from Nobel Laureate Shimon Sakaguchi: immunology.org/publications...

🧬 New in Immunotherapy Advances:

Cytokine-induced memory-like NK cells + Tafasitamab show strong efficacy against B-cell ALL, boosting cytotoxicity & survival in vivo.

Open Access 👉 https://bit.ly/48oztXa

#Immunotherapy #NKcells

graphical abstract for Strategies to overcome low MHC-I expression in paediatric and adult tumours

🧬 Low MHC-I expression can help tumours evade the immune system.

Discover strategies to boost MHC-I and improve immunotherapy in paediatric and adult cancers. 🔬

Read: https://bit.ly/45vtfmp

#Immunotherapy #CancerResearch #MHCI

graphical abstract for Tumour-reactive plasma cells in antitumour immunity: current insights and future prospects

💡 Tumour-reactive plasma cells are emerging as powerful players in cancer immunotherapy!

Explore their role in antibody-based, personalized treatments. 🔬

Read: https://bit.ly/3SVZsMC

#Immunotherapy #CancerResearch #PlasmaCells

graphical abstract of Harnessing natural killer cell effector function against cancer

💥Open Access review: NK cells as cancer fighters!

From CAR-NK cells to checkpoint inhibitors, explore cutting-edge strategies to harness NK-cell immunity. 🔬

Read: https://bit.ly/4j8dKEW

#Immunotherapy #NKcells #CancerResearch

Could CD200R blockade enhance PD-1 therapy?

A humanised mouse study found limited benefit in colorectal & lung cancer, but points to potential in CD200⁺ tumours.

🔗 https://bit.ly/4pdAtDw

#Immunotherapy #CancerResearch

Exploring the role of DC3s in solid tumours! These dendritic cells can boost anti-tumour immunity or contribute to immunosuppression depending on the TME.

Discover their potential for targeted therapies 👉 https://bit.ly/3T2blRg

#EMDS2025 #Immunotherapy #CancerResearch

TAMs drive tumour progression, metastasis & therapy resistance.

Targeting their surface receptors may unlock new cancer immunotherapy strategies, insights for #EMDS2025

🔗 https://bit.ly/4i95qnm

Could JAK inhibitors be a treatment for STAT3 gain-of-function?

Study shows symptom improvement in patients with this rare immune disorder.

Read here🔗 https://bit.ly/4p7Vxer

#Immunotherapy

⏳ Last chance! Submit your research on immunotherapies for inborn errors of immunity to our Special Collection before the end of September.

Submit here: https://bit.ly/4p96dJA

#Immunology

It's the final day of Cancer Immunology: Advances & Therapeutic Application, don’t miss our journals manager Laura Franklin giving a talk at 11:00 AM today!

Learn more about publishing opportunities and journal initiatives.

#CancerImmunology #Immunotherapy

Are you attending Cancer Immunology: Advances & Therapeutic Application and working on cancer vaccines?
Share your latest research in our Special Collection on global advances, personalised or off-the-shelf vaccines, clinical trials & more.

Submit here: https://bit.ly/4mPbW64

Attending Cancer Immunology: Advances & Therapeutic Application?

Come and visit us at our booth to learn more about our journals, upcoming special collections, and opportunities to publish! #CancerImmunology #Immunology

NLRP3 inflammasome activation in sensory neurons drives chronic inflammatory & osteoarthritis pain.

Blocking this pathway may offer a route to new treatments.

Read more🔗 https://bit.ly/3UX7Tbz

#ChronicPain #Immunology

Working on targeted therapies for inborn errors of immunity?

Our Special Collection on genetics-guided immunotherapy closes at the end of this month, submit your research today!

Learn more: https://bit.ly/4p96dJA

🚀 Going viral against #Glioblastoma!

Discover how oncolytic viruses are reshaping the immune landscape of GBM, boosting therapy response & offering new hope.

Open Access 👉 https://bit.ly/3UMBhkw #Immunotherapy #CancerResearch

High-affinity TCR bispecific (ImmTAC®) redirects T cells to efficiently kill PRAME+ tumor cells across multiple cancers. Combination with PD-1 blockade may enhance activity.

By Ribeiro et al.

🔗 https://bit.ly/40o5kT8

#Immunotherapy #CancerResearch #PRAME

💉 During #ImmunisationAwarenessMonth, a timely reminder: mRNA COVID-19 vaccines (Pfizer & Moderna) remain highly effective at preventing hospitalisation (84–86%), even with variant challenges.

🔗 https://bit.ly/43rUWvP

#Vaccineswork #immunology

💉 Cancer vaccines are regaining momentum with advances in neoantigen science, tumour mutational burden & mRNA technology.

A deeper understanding of dendritic cells and immune mechanisms is key to unlocking their full potential. 🚀

#ImmunisationAwarenessMonth

🔗 https://bit.ly/4cefxGm

Why are paediatric tumours less responsive to immunotherapy?

One reason: MHC-I downregulation. Restoring it could make tumour cells visible again to CD8 T cells.

🔗 https://bit.ly/45vtfmp

Smallpox vaccines provide important cross-protection against Mpox. Evidence from past outbreaks informed the use of the MVA–BN vaccine during 2022, highlighting how immunisation strengthens preparedness for emerging threats.

#NationalImmunisationAwarenessMonth

👉 https://bit.ly/4jSbodz

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment graphical abstract

Bispecific T-cell engagers (BiTEs) redirect T-cells to attack tumors, but their power is often limited by immune checkpoints & suppressive microenvironments.

💡 Combination strategies with checkpoint inhibitors, chemo, or oncolytic viruses could boost effectiveness.

👉 https://bit.ly/4oKabbt